In response to the continued interest of stakeholders around the world, the USPTO has extended the Patents 4 Patients Cancer Immunotherapy Pilot Program through June 30, 2020. All pilot parameters remain the same as first implemented on June 29, 2016.
The Extended Missing Parts Pilot Program has not been extended and will end January 2, 2019 as scheduled.
|